StreetInsider.com News Articles

Jasper Therapeutics completes IgAN cohort enrollment in Phase 2 study

Thu, 15 Oct 2026 08:02:05 -0400

Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the completion of enrollment in the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a bifunctional biologic targeting both the alternative and terminal complement pathways.

A total of 18 patients with IgAN were enrolled in stage 1 of the study across three cohorts. Each cohort of six patients is evaluating an induction regimen followed by subcutaneous maintenance dosing at different intervals: every two weeks, every four weeks, or every eight weeks. The stage 1 objective is to assess safety, tolerability, and initial efficacy in IgAN, and to help determine

Form 8-K Jasper Therapeutics, For: Oct 15

Thu, 15 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261015/27189918.html

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Thu, 15 Oct 2026 08:00:00 -0400

Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026

Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027

REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a first-in-class bifunctional

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Thu, 15 Oct 2026 08:00:00 -0400

Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026

Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027

Form S-3 Jasper Therapeutics,

Wed, 14 Oct 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20261014/27187942.html

William Blair Resumes Jasper Therapeutics (JSPR) at Outperform

Wed, 14 Oct 2026 05:44:03 -0400

(Updated - October 14, 2026 5:44 AM EDT)

William Blair analyst Matt Phipps resumes coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Outperform rating.

The analyst comments "Our Outperform rating is largely based on the potential of the bifunctional molecule KP-104 to deliver best-in-class efficacy for complement-mediated diseases through the inhibition of the terminal complement pathway and modulation of the alternative complement pathway. Therefore, KP-104 can prevent MAC formation and C3b opsonization, two independently validated therapeutic mechanisms in several complement-mediated diseases, including: paroxysmal nocturnal hemoglobinuria (PNH), complement 3 glomerulopathy (C3G), and IgA nephropathy (IgAN). Clinical results with KP104 have validated this approach

William Blair Resumes Jasper Therapeutics (JSPR) at Outperform

Wed, 14 Oct 2026 05:44:03 -0400

(Updated - October 14, 2026 5:44 AM EDT)

William Blair analyst Matt Phipps resumes coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Outperform rating.

Form PRE 14A Jasper Therapeutics, For: Oct 09

Fri, 09 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261009/27172106.html

Form 8-K Jasper Therapeutics, For: Oct 07

Wed, 07 Oct 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27158326.html

Jasper Therapeutics launches offer to buy back outstanding warrants

Wed, 07 Oct 2026 08:03:39 -0400

Jasper Therapeutics, Inc. (Nasdaq: JSPR) has commenced an offer to purchase all of its outstanding warrants, which were originally issued in an underwritten public offering on September 18, 2025, according to a press release.

The company is offering $0.324 in cash per warrant, with no interest. As of October 6, 2026, there were 12,345,707 warrants outstanding. If all warrants are tendered, the total payout would be approximately $4.0 million, to be funded from cash on hand.

Each warrant entitles its holder to purchase one share of common stock at an exercise price of $2.92, subject to adjustment. Warrants not tendered will remain

Jasper Therapeutics launches offer to buy back outstanding warrants

Wed, 07 Oct 2026 08:03:39 -0400

Each warrant entitles its holder to purchase one share of common stock at an exercise price of $2.92, subject to adjustment. Warrants not tendered will remain

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Wed, 07 Oct 2026 08:00:00 -0400

REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Wed, 07 Oct 2026 08:00:00 -0400

Form SC TO-I Jasper Therapeutics, Filed by: Jasper Therapeutics, Inc.

Wed, 07 Oct 2026 07:51:00 -0400

si-local-file:///var/storage/secattach/20261007/27158054.html

Form 8-K Jasper Therapeutics, For: Sep 30

Mon, 05 Oct 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20261005/27145968.html

Form 8-K/A Jasper Therapeutics, For: Jul 16

Mon, 05 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261005/27145046.html

Form 8-K/A Jasper Therapeutics, For: Jul 16

Thu, 01 Oct 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20261001/27137366.html

Form 8-K Jasper Therapeutics, For: Sep 23

Mon, 28 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260928/27115184.html

Form 25-NSE Jasper Therapeutics, Filed by: Nasdaq Stock Market LLC

Thu, 24 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260924/27102384.html

Jasper Therapeutics names two executives to regulatory and clinical roles

Tue, 15 Sep 2026 16:06:08 -0400

Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the appointments of Lisa Pitt as Senior Vice President of Regulatory Affairs and Shiguang Liu as Vice President of Clinical Development, according to a company press release.

Pitt brings over 25 years of experience in regulatory and medical affairs across industry and the U.S. Food and Drug Administration. She most recently served as Vice President of Regulatory Affairs at Aiolos Bio before its acquisition by GlaxoSmithKline. She has also held regulatory roles at NorthSea Therapeutics, Horizon Therapeutics, Viela Bio, AstraZeneca, and Novartis. At the FDA, she served as Senior Regulatory Health Project Manager at the

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Tue, 15 Sep 2026 16:05:00 -0400

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs

Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development

REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.

“We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Tue, 15 Sep 2026 16:05:00 -0400

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs

Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development

“We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.

H.C. Wainwright 28^thAnnual Global Investment Conference
Presentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ET
Presentation Format: Fireside Chat

A live webcast of the fireside chat will be available on the News

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

H.C. Wainwright 28^thAnnual Global Investment Conference
Presentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ET
Presentation Format: Fireside Chat

A live webcast of the fireside chat will be available on the News

Form 8-K Jasper Therapeutics, For: Aug 21

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26981985.html